Acutaas Chemicals Limited announced strong financial results for the second quarter and first half of FY27. Revenue grew 42.7% YoY to ₹4,369 million, with EBITDA up 84.6% YoY. The company has revised its full-year revenue growth guidance to 25%-30% and raised EBITDA margin guidance to 38%-40%. Management highlighted growth across Pharmaceutical Intermediates, CDMO, and Specialty Chemicals, including Battery and Semiconductor chemicals.
Acutaas Chemicals Reports Robust Q2 FY27 Performance
Acutaas Chemicals Limited has announced its financial results for the second quarter and the first half of the fiscal year 2027. The company demonstrated strong performance across its key business segments, reflecting robust demand and effective operational strategies.
Key Financial Highlights
Quarterly Performance (Q2 FY27)
- Revenue from Operations: ₹4,369 million, a growth of 42.7% year-on-year.
- Gross Profit: ₹2,715 million, a 59% increase compared to the same period last year, with gross margins expanding by 637 basis points to 62.1%.
- EBITDA: ₹1,760 million, up 84.6% year-on-year, with EBITDA margins at 40.3%, an improvement of 914 basis points.
- PAT: ₹1,231 million, up 71.4% year-on-year, with PAT margins at 28.2%.
Half-Yearly Performance (H1 FY27)
- Revenue from Operations: ₹7,666 million, a growth of 49.3% year-on-year.
- EBITDA: ₹2,890 million, up 97.7% year-on-year, with EBITDA margins at 37.7%.
- PAT: ₹1,981 million, up 71% year-on-year, with PAT margins at 25.8%.
Revised Guidance and Outlook
The company has revised its revenue growth guidance for the current fiscal year from 25% to around 30%. Furthermore, Acutaas Chemicals has raised its EBITDA margin guidance to the range of 38%-40% for FY27.
Regarding CAPEX, the company invested ₹1,239 million in H1 FY27 across various projects. The total CAPEX for the full year is projected to be around ₹3,000 million, with an additional ₹1,650 million planned for H2 FY27, including significant allocations for electronic-grade chemicals and the electrolyte additive project.
Business Segment Updates
Pharmaceutical Intermediates & CDMO
The Pharmaceutical Intermediate business showed robust performance, with revenues of ₹4,020 million in Q2 FY27, a growth of 53.1% year-on-year. The CDMO business continues its strong growth trajectory. The company anticipates achieving its ambition of ₹1,000 crores in CDMO revenue by FY27, a year ahead of its initial schedule. The long-term target is to double CDMO revenue to ₹2,000 crores by FY30.
Specialty Chemicals
The Specialty Chemicals segment recorded revenues of ₹349 million in the quarter, a decrease of 20% YoY, primarily due to the phasing out of legacy commodity products and a temporary pause in BFC shipments. However, shipments have resumed, and the company expects growth in this segment. The company inaugurated its semiconductor chemicals plant in South Korea and is submitting qualification batches to customers. Battery chemicals have started contributing to revenue, with positive early traction.
Forward-Looking Statements
The management noted that statements made during the call regarding the company’s outlook and future prospects should be reviewed in conjunction with the risks the company may face. The transcript and audio of the conference call will be available on the company’s website and stock exchanges.
Source: BSE
